US Stem Cell (OTCMKTS:USRM) and National Research (NASDAQ:NRC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

39.7% of National Research shares are owned by institutional investors. 16.7% of US Stem Cell shares are owned by insiders. Comparatively, 4.5% of National Research shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for US Stem Cell and National Research, as provided by MarketBeat.com.

Volatility & Risk

US Stem Cell has a beta of 4.87, meaning that its stock price is 387% more volatile than the S&P 500. Comparatively, National Research has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.

Valuation and Earnings

This table compares US Stem Cell and National Researchs gross revenue, earnings per share (EPS) and valuation.

National Research has higher revenue and earnings than US Stem Cell.

Profitability

This table compares US Stem Cell and National Researchs net margins, return on equity and return on assets.

Summary

National Research beats US Stem Cell on 7 of the 9 factors compared between the two stocks.

US Stem Cell Company Profile

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

National Research Company Profile

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Companys portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Companys clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.

Receive News & Ratings for US Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for US Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
National Research (NASDAQ:NRC) versus US Stem Cell (NASDAQ:USRM) Head-To-Head Review - Riverton Roll

Cardiac Stem Cells Comments Off on National Research (NASDAQ:NRC) versus US Stem Cell (NASDAQ:USRM) Head-To-Head Review – Riverton Roll | January 22nd, 2020

5 Ways To Stay Healthy If You Sit All Day At Work

Ever since the 1966 film 'Fantastic Voyage', an American science-fiction about a submarine crew who are shrunk to microscopic size and venture into the body of an injured scientist to repair damage to his brain, it remained a possible conception for robotic engineers too.

Now, a team of scientists from the University of Vermont has succeeded by repurposing living cells of frog embryos into entirely new millimeter-long life-forms, called "xenobots", which can move toward a target, carry a payload, say, a medicine and reache a specific body part of a patient.

"These are novel living machines," says Joshua Bongard, a computer scientist and robotics expert at the University of Vermont, part of the research team. "They're neither a traditional robot nor a known species of animal. It's a new class of artifact: a living, programmable organism."

Bongard says they tried to slice the robot almost in half and found it stitching itself back up and moving ahead. This is "somtheing you can't do with typical machines. These xenobots are fully biodegradable. When they're done with their job after seven days, they're just dead skin cells," explained Bongard.

Initially designed on a supercomputer and then assembled and tested by biologists at Tufts University, these robots can have many useful applications as first batch of living robots that other machines cannot become, said Michael Levin, team member and director of Center for Regenerative and Developmental Biology at Tufts.

Some of the applications include searching out nasty compounds or radioactive contamination, gathering microplastic in the oceans, traveling in arteries to scrape out plaque. The results of the new research were published January 13 in the Proceedings of the National Academy of Sciences.

The team used an evolutionary algorithm to create thousands of candidate designs for the new life-forms, which can carry out a task like locomotion in one direction. First they gathered stem cells, harvested from the embryos of African frogs, the species Xenopus laevis, which led to its name "xenobots."

Assembled into body forms never seen in nature, the cells formed a more passive architecture, while the once-random contractions of heart muscle cells were put to work creating ordered forward motion and aided by spontaneous self-organizing patterns -- allowing the robots to move on their own.

Later, tests showed that groups of xenobots would move around in circles, pushing pellets into a central location -- spontaneously and collectively. "It's a step toward using computer-designed organisms for intelligent drug delivery," says Bongard.

The rest is here:
These robots made of living frog cells are meant to revolutionize treatment methods - International Business Times, Singapore Edition

Skin Stem Cells Comments Off on These robots made of living frog cells are meant to revolutionize treatment methods – International Business Times, Singapore Edition | January 22nd, 2020

Formosa's plastics plant is seen dominating the landscape in Point Comfort, Texas. Julie Dermansky / DeSmogBlog

Diane Wilson is seen with volunteers before their meeting across the street from Formosa's Point Comfort manufacturing plant. Julie Dermansky / DeSmogBlog

Within 10 minutes she collected an estimated 300 of the little plastic pellets. Wilson says she will save them as evidence, along with any additional material the group collects, to present to the official and yet-to-be-selected monitor.

Wilson received the waiver forms from Formosa a day after the deadline. The group planned to set out by foot on Jan. 18, which would allow them to cover more ground on their next monitoring trip. They hope to check all of the facility's 14 outtakes where nurdles could be still be escaping. Any nurdles discharged on or after Jan. 15 in the area immediately surrounding the plant would be in violation of the court settlement.

Ronnie Hamrick picks up a mixture of new and legacy nurdles near Formosa's Point Comfort plant. Julie Dermansky / DeSmogBlog

Ronnie Hamrick holds a few of the countless nurdles that litter the banks of Cox Creek near Formosa's Point Comfort facility. Julie Dermansky / DeSmogBlog

Lawsuit Against Formosas Planned Louisiana Plant

On that same afternoon, Wilson learned that conservation and community groups in Louisiana had sued the Trump administration, challenging federal environmental permits for Formosa's planned $9.4 billion plastics complex in St. James Parish.

The news made Wilson smile. "I hope they win. The best way to stop the company from polluting is not to let them build another plant," she told me.

The lawsuit was filed in federal court against the Army Corps of Engineers, accusing the Corps of failing to disclose environmental damage and public health risks and failing to adequately consider environmental damage from the proposed plastics plant. Wilson had met some of the Louisiana-based activists last year when a group of them had traveled to Point Comfort and protested with her outside Formosa's plastics plant that had begun operations in 1983. Among them was Sharon Lavigne, founder of the community group Rise St. James, who lives just over a mile and a half from the proposed plastics complex in Louisiana.

Back then, Wilson offered them encouragement in their fight. A few months after winning her own case last June, she gave them boxes of nurdles she had used in her case against Formosa. The Center for Biological Diversity, one of the environmental groups in the Louisiana lawsuit, transported the nurdles to St. James. The hope was that these plastic pellets would help environmental advocates there convince Louisiana regulators to deny Formosa's request for air permits required for building its proposed St. James plastics complex that would also produce nurdles. On Jan. 6, Formosa received those permits, but it still has a few more steps before receiving full approval for the plant.

Anne Rolfes, founder of the Louisiana Bucket Brigade, holding up a bag of nurdles discharged from Formosa's Point Comfort, Texas plant, at a protest against the company's proposed St. James plant in Baton Rouge, Louisiana, on Dec. 10, 2019. Julie Dermansky / DeSmogBlog

Construction underway to expand Formosa's Point Comfort plant. Julie Dermansky / DeSmogBlog

Silhouette of Formosa's Point Comfort Plant looming over the rural landscape. Julie Dermansky / DeSmogBlog

From the Gulf Coast toEurope

Just a day after Wilson found apparently new nurdles in Point Comfort, the Plastic Soup Foundation, an advocacy group based in Amsterdam, took legal steps to stop plastic pellet pollution in Europe. On behalf of the group, environmental lawyers submitted an enforcement request to a Dutch environmental protection agency, which is responsible for regulating the cleanup of nurdles polluting waterways in the Netherlands.

The foundation is the first organization in Europe to take legal steps to stop plastic pellet pollution. It cites in its enforcement request to regulators Wilson's victory in obtaining a "zero discharge" promise from Formosa and is seeking a similar result against Ducor Petrochemicals, the Rotterdam plastic producer. Its goal is to prod regulators into forcing Ducor to remove tens of millions of plastic pellets from the banks immediately surrounding its petrochemical plant.

Detail of a warning sign near the Point Comfort Formosa plant. The waterways near the plant are polluted by numerous industrial facilities in the area. Julie Dermansky / DeSmogBlog

Nurdles on Cox Creek's bank on Jan. 15. Wilson hopes her and her colleagues' work of the past four years will help prevent the building of more plastics plants, including the proposed Formosa plant in St. James Parish. Julie Dermansky / DeSmogBlog

A sign noting the entrance to the Formosa Wetlands Walkway at Port Lavaca Beach. The San Antonio Estuary Waterkeeper describes the messaging as an example of greenwashing. Julie Dermansky / DeSmogBlog

From Your Site Articles

Related Articles Around the Web

More here:
Scientists Combine AI With Biology to Create Xenobots, the World's First 'Living Robots' - EcoWatch

Skin Stem Cells Comments Off on Scientists Combine AI With Biology to Create Xenobots, the World’s First ‘Living Robots’ – EcoWatch | January 22nd, 2020

Over the last three decades, Ken Aldrich has successfully invested in over 50 businesses and has personally co-founded almost a dozen himself. He considers himself a jack of all trades, having been involved in everything from biomedicine to real estate. Some of his most successful investments include helping start one of the first wind parks in Palm Springs and Green Dot Corp. (NYSE:GDOT), which has become the worlds largest prepaid debit card company. In May, Aldrich published his book, "Dream Toolbox," which aims to guide readers toward establishing an entrepreneurial mind and gaining control over their financial world.

Before the business

Prior to entrenching himself as an entrepreneur, Aldrich started his career as a wage earner practicing law. He spent a great deal of time and effort to earn his law degree and land a spot in a well-established firm. With a clear career path ahead of him, Aldrich got to work earning his keep and establishing his position in the firm. However, one definitive moment stands out as the time when he became dissatisfied with his work.

This moment would revolve around sandwiches of all things. Working alongside one of the senior partners at the firm, Aldrich was helping to create a registration statement for a public company. At the end of the session that fateful day, the underwriters and the people from the company headed out to get dinner:

At the end of the day the company and the firm that was doing the underwriting turned to us, the lawyers, and said Well that was really good. Can we have a new draft of the work in the morning at nine and we will start again? Off they went to have dinner at Chasens and we ordered sandwiches, Aldrich said.

To provide context for those who do not know the Los Angeles restaurant history, Chasens was a well-known restaurant that was often frequented by famous celebrities until its closing in 1995. Based upon the prestige of the restaurant's chili, it is easy to conceive a distaste for sandwiches after a long day at work.

While in his 20s Aldrich did not have an issue eating sandwiches, yet he was thinking toward his future. My partner, that I was working for, was in his 30s or 40s. I do not want to be the guy eating sandwiches in his 30s or 40s, and I do not care how much they pay me for it, Aldrich said. It was in this moment that he decided that he would much prefer to be the guy going out for a nice dinner after work.

With clear motivation, Aldrich set out to find himself a new career path. He landed himself a contractual position at an investment banking firm. This provided him with some needed experience and training, alongside a foot in the door with a name behind him. This new venture would come with an inherent risk, one that Aldrich would feel almost immediately.

Working at the law firm, he had earned himself a paycheck and a solidified position. Upon leaving, that paycheck disappeared. To compound the pressure, Aldrich was working on a contract for the investment banking firm, meaning that if he were to no longer be productive in their eyes, he would be cut from their team. In essence, the already large pay cut he had taken could go away in an instant. He went on to say:

Wide World of Sports had a sports program on Saturday and their opening montage was a skier, it might have been a tobogganer, coming down a ski run and losing control and flying head over heels into a snowbank. The tagline was Wide World of Sports, the thrill of victory and the agony of defeat. I realized that with conventional jobs you are either working for a paycheck or in the case of a lawyer you are measuring your life out in coffee spoons as Eliot once said in a poem. There is never the chance of a real thrill of victory. The expectation is do not screw up and I wanted something more than that.

Finding success

With a drive to succeed and find that thrill of victory, Aldrich set out on his journey to become a successful entrepreneur. By nature of the business, he would find himself in the world of seed stage venture capital, investing and co-founding businesses from the ground up. Through both luck and skill, he was able to grow many of these businesses to success, yet there is seemingly no connection between them. However, Aldrich considers himself a jack of all trades and finds that his curiosity has led him to such diverse portfolio.

While he has found himself invested in many different fields, there is one key factor that ties them all together. If there is technology involved, I want to make sure that if it is successful, often it is not completely developed when we start, but that if it is successful it will make a fundamental change in some business, or industry, or science, Aldrich said. Having this significant change in the way things are done makes either the business or the product stand out in a way that the market cannot deny. For Aldrich, this is key for these types of ventures to be a success.

It is very hard to be successful starting a new business if you are just doing it a little bit better because, you know, everybody is looking for perfect, but perfect is the enemy of the good. If there is an existing process that is serving the market adequately it is usually just a fools errand to try to make something else that is just a little bit better, he continued.

As with many lessons, Aldrich had to learn to make fundamental changes first hand. One of the first businesses he found himself involved in was working to develop a new device for LASIK procedures. This device would allow for the surgeon to be more accurate when applying the procedure. Initially, the company found success in that the device did improve the accuracy of the procedure. However, it was not a big enough difference and nobody cared according to Aldrich.

Going back to the drawing board, the company went about redesigning the product so that it could be an aid to curing amblyopia in children, yet the market there was too small. With the aid of an ocular physician, the company found its true purpose. The new design would allow a surgeon in the process of doing cataract surgery to take an accurate measurement of the eye.

Prior to this new design, the surgeon would attempt to measure the eye through the clouded portion as best as possible before removing the affected area. As the measurement had to be taken through the affected area, it was generally not overly accurate and that is how people ended up with those coke bottle glasses, Aldrich said.

With their newly pioneered technology, the surgeon had a new device that would attach to the microscope that they used during the procedure. This would allow for them to take an accurate measurement of the lens of the eye prior to the surgery. This technology resulted in vision on par with a LASIK procedure as a byproduct of conventional cataract surgery. It was very gratifying for me because I have, over my life, had enough eye problems to realize just how life changing that small procedure can be, Aldrich said. This business would eventually go on to sell for $350 million.

Managing risk

With the prospect of millions, if not billions, on the horizon, there is constant risk involved with starting these businesses. For Aldrich, the key to success comes in managing this risk, although it can never be entirely eliminated. Once he has established that the technology or the business will make a fundamental change in the industry it operates in, he looks toward the people involved. First and foremost, he questions if they have enthusiasm and skin in the game as he calls it. Now that does not necessarily mean that they have written big checks, but they have put some portion of their life on hold to pursue this, he said.

Finding a person who fits these qualities allows for Aldrich to be confident that if things get difficult with the company, nobody is going to give up. In many cases, things do go wrong when starting a business. Very rarely does a business make its way to success without encountering a road bump. At some point everyone has to take some genuine risk. I have never known a startup that did not involve that, Aldrich said.

Over the course of 30 years in business, Aldrich has experienced his fair share of risk and road bumps. One of the most egregious cases that he recalled involved a biotechnology company. The company in question was working to develop new stem cells similar in nature to embryonic stem cells. The winning factor was that the company had found a way to access these cells without needing a fertilized embryo. So we took all, or we thought we took all of them, some people still managed to find objections, but we took basically all the real objections away from those who were concerned, for religious or for other reasons, with whether or not using embryonic stem cells was in effect killing a human being in utero, Aldrich said.

While they had overcome a major roadblock to progress their research, they still had not reached calm seas. The company would go public and found itself in the midst of the economic downturn of 2008. Almost overnight, funding that had been promised had disappeared and the company was left stranded with no backing.

To further compound issues, the CEO of the company died of a heart attack shortly after. Aldrich found himself running the company and as an investor himself. He put forth a check for $500,000, one that would have been very painful to have lost in his own words. In a stroke of luck, he was able to find an investor for the company. However, the man was in Paris, was Russian and spoke no English. Not a man to be stopped, Aldrich flew to Paris, dug up a translator on the eve of a French holiday and made a deal with the new investor.

With the help of this new partner and his own investment, Aldrich would pull the company out of the hole it found itself in. The company would continue to make progress on its stem cell research. Eventually, the majority shareholder of the company would push Aldrich out of a leadership position and he decided it would be best to pull himself out of the company entirely. During his time there, Aldrich would grow the stock from 15 cents per share to over $2 per share.

The biggest perks

While Aldrich has undoubtedly seen rough times working with companies, he has found himself, more often than not, in the position of successfully creating a business. The thrill of just saying, I did that, claimed Aldrich, is one of the best parts of what he does. Continuously, he has had the ability to take the vision that someone brings him and help them turn it into a reality. For him that has been extremely gratifying, yet he has been able to take it one step further.

Many of the companies that he has been involved in have changed people's lives for the better. The first LASIK company aided many people in having better vision, which Aldrich considers life changing. The stem cell company has the potential to change the way stem cells are used, and he believes they ultimately will. Even present day he is working with a company that is working to make chemotherapy drastically more effective to the point that it can cure certain types of cancers.

Without a doubt Aldrich has found the thrill of victory and helped people in the process. Now it is still a whole lot of fun to make money from a deal and see it take off, he said. One of his most ludicrous investments was Green Dot Corp., in which he was an early investor. Since throwing his hat in the ring, the company has not only reached a billion-dollar market cap, it has created an entirely new industry of prepaid debit cards.

Even the wind park in Palm Springs that Aldrich helped start has seen him cashing monthly checks from land rights for the last 20 years. Having both built companies and earned money for decades, it is easy to understand how he has no desire to change anything, yet Aldrich believes that he has no regrets for a different reason.

I think in each case we did the most we could do with what we had available, Aldrich said. In his opinion, there will always be something that could have gone differently or a potential to have found greater success. The reality is I had gone everywhere I could think of and took the option that was available, he continued.

In the end, worrying becomes unproductive. It creates a situation in which you are cautious about your current ventures and begin to question every decision. Aldrich believes this type of fear, the fear of failure, is one that is extremely detrimental to an entrepreneur. Overcoming this fear has been key to his success.

No end in sight

In his most recent ventures, Aldrich has found himself seeking to inspire both youth and entrepreneurs alike. He has spent time working with at-risk teenagers to provide them with financial lessons as well as the skills to develop their dreams into reality. From these lessons, Aldrich developed a podcast series that would eventually become his first book, titled "Dream Toolbox," for anyone frustrated by unfulfilled dreams.

Although Aldrich has had a career outlasting many other entrepreneurs, he does not believe he will ever be able to stop. While he has made a promise to himself to not start any new companies, he will continue to fund and advise them as much as he can:

I can not see stopping because, frankly, it is so darn much fun. I have flunked retirement several times in the sense of really trying to turn it off. What I have discovered is just about the time I am getting all excited to go play a round of golf, or go play tennis or something like that, somebody will call me up with a new idea, or a new concept, and I will cancel the golf or cancel the tennis because nothing is more exciting than dealing with a new idea that has great promise.

Question and answer

GuruFocus: As an entrepreneur, and a serial entrepreneur at that, is there anything in the future coming up or already starting to reach the market that you are really excited about and would love to get your hands on?

Aldrich: My experience has been that the things that are already visible to me, out there in the market, somebody else has already started and is way ahead of me. So what I am looking for are the things that are not yet obvious and those can come in many ways. I recently became an investor in a company. It is not a startup anymore. I invested through some friends, but it is very exciting. They have, I believe, a way to, I will not say cure, but to take any of the existing chemotherapies that are used in cancer and make them way, way more effective, and the reality is, based upon the data we have, in many cases cure cancers that the physicians had given them up as incurable and a death sentence. That is enormously exciting to me and I think that we will see that.

I have also invested, although I am not a principle, in three or four other companies that have varying ways of approaching, particularly cancer, but other disease forms. That to me is an exciting area and I think we are just beginning to scratch the surface of what can be done medically. There are things going on with AI that will affect the medical world. I read in this mornings newspaper about a new AI technique that I think was developed by Google that has greatly improved the accuracy, or looks like it has greatly improved the accuracy of mammograms. That could be life-saving.

GuruFocus: Where do you look for inspiration?

Aldrich: One of the great books and it is overlooked, but I think everybody should read it right after they finish mine, actually before, is "Think and Grow Rich." Which has been around for almost a century, I guess. It is absolutely a brilliant set of ideas and structures for entrepreneurship. There are certainly more modern books. I happen to like Peter Thiels book, which I think he calls "Zero to One." It talks about entrepreneurship and finding a niche that you can fill and expand into making something big. Of course, if you just start looking and get specific, there are tons and tons of books on how to structure a business, how to handle the accounting, finance and so on. Again, I think it starts with changing the belief systems so that you believe you can do it and for that there probably is no better book that I have read than "Think and Grow Rich."

GuruFocus: What are you most grateful for at this point in your life?

Aldrich: Oh wow. I am most grateful that I have had the incredible good fortune to have the love of not one, but two wonderful women in my life. First my wife, who died a few years ago, and second, the woman who is now sharing my life. That has been remarkable. I have also had the good fortune through most of my life of having good health. I have had plenty of health issues that I have had to deal with, but they have all been like the puzzles I talked about. OK, I have a problem. I had a vision problem. I have had other things. How can we solve them? So far, they have all been soluble. I have been very fortunate. As you can see from this ugly photograph on your screen, I am not a young man anymore. I wake up in the morning thinking I am at least 20 or 30 years younger than I am until I look in the mirror. And that is a good thing because age ultimately matters as none of us live forever. In terms of our capacity to do things, it is how we view ourselves, so that is important.

Aldrichs advice for entrepreneurs

Have a vision both personally and in business:

Try to visualize what life would look like if you were to find the success that you have. Once you have this vision, there is something for you to strive for. In Aldrichs opinion, this is one of the most powerful tools an entrepreneur can utilize. Visualize yourself being successful while standing in front of the mirror. It may feel stupid at first, as it did for Aldrich, but you will eventually make that vision a reality by translating it into the present. Use your vision to tell yourself that you are successful now and, before you realize it, you will have reached many of your early milestones.

Put some skin in the game:

It can be simplified to one word: commit. You need to absolutely dedicate yourself to what you are doing if you want to succeed. This will require personal sacrifice. Your life will not continue to exist in the same way that it had previously and you have to be OK with that. Once you have committed your life to achieving your goals and truly put some skin in the game, you will find success. If you do not do this, you are going to give up when things get tough.

Determine if the worst outcome is survivable:

Another of Aldrichs most powerful tools is determining if the worst possible outcome is survivable. Look at the worst thing that could happen in the course of starting this business. Are you looking at bankruptcy? Or could it be something personal that ends life as you know it? Once you have determined what could happen, you need to decide if you have the ability to keep going on after that. If you can survive the worst outcome, than there is nothing that can stop you on your journey. All your problems become puzzles that have a solution. You simply need to find it.

For more information on Ken Aldrich and Dream Toolbox visit:

https://www.dreamtoolbox.com/

If you are an entrepreneur or know one that would be a good fit for our series, please fill out the questionnaire and our editorial team will reach out as soon as possible.

Make sure to check out the podcast.

Watch the video of the entire interview here:

Read more here:

Not a Premium Member of GuruFocus? Sign up for afree 7-day trial here.

Read the original:
1000 Entrepreneurs: Ken Aldrich on 30 Years of Venture Capital and 50 Successful Businesses - GuruFocus.com

Skin Stem Cells Comments Off on 1000 Entrepreneurs: Ken Aldrich on 30 Years of Venture Capital and 50 Successful Businesses – GuruFocus.com | January 22nd, 2020

Automobile Antenna Market Overview Forecast To 2028

The research report contains a detailed summary of the Global Automobile Antenna Market that includes various well-known organizations, manufacturers, vendors, key market players who are leading in terms of revenue generation, sales, dynamic market changes, end-user demands, products and services offered, restricted elements in the market, products and other processes. Technical advancements, market bifurcation, surplus capacity in the developing Automobile Antenna markets, globalization, regulations, production and packaging are some of the factors covered in this report.

The research report on Global Automobile Antenna Market is a detailed study of the current market scenario, covering the key market trends and dynamics. The report also presents a logical evaluation of the major challenges faced by the leading market players operating in the market, which helps the participants to understand the barriers and challenges they may face in future while functioning in the international market over the forecast 2020-2028.

The following manufacturersare assessed in this report in terms of sales, revenue, and market share for each company:Kathrein, Harada, Laird, Yokowa, Northeast Industries, Hirschmann, Suzhong, Ace Tech, Fiamm, Tuko, Inzi Controls, Shenglu, Riof, Shien, Tianye

Geta PDF SampleCopy (including TOC, Tables, and Figures) @https://garnerinsights.com/2013-2028-Report-on-Global-Automobile-Antenna-Market-by-Player-Region-Type-Application-and-Sales-Channel#request-sample

Types of Automobile Antenna covered are: Fin TypeRod TypeScreen TypeFilm TypeIntegrated TypeOthers

Applications of Automobile Antenna covered are: Passenger VehicleCommercial Vehicle

The Global Automobile Antenna Market report analyses the production of goods, supply, sales, and the current status of the market in a detailed manner. Furthermore, the report examines the production shares and market product sales, as well as the capacity, production capacity, trends in sales, cost analysis, and revenue generation. Several other factors such as import/export status, industrial statistics, demand and supply ratio, gross margin, and industry chain structure have also been studied in the Global Automobile Antenna Market report.

To get this report at a profitable rate, Click Herehttps://garnerinsights.com/2013-2028-Report-on-Global-Automobile-Antenna-Market-by-Player-Region-Type-Application-and-Sales-Channel#discount

Regional Analysis For Automobile AntennaMarket

North America(the United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Get Full Report Description, TOC, Table of Figures, Chart, etc. @https://garnerinsights.com/2013-2028-Report-on-Global-Automobile-Antenna-Market-by-Player-Region-Type-Application-and-Sales-Channel

Table of Contents:

Study Coverage:It includes key manufacturers covered, key market segments, the scope of products offered in the global Automobile Antennamarket, years considered, and study objectives. Additionally, it touches the segmentation study provided in the report on the basis of the type of product and application.

Executive Summary:It gives a summary of key studies, market growth rate, competitive landscape, market drivers, trends, and issues, and macroscopic indicators.

Production by Region:Here, the report provides information related to import and export, production, revenue, and key players of all regional markets studied.

Profile of Manufacturers:Each player profiled in this section is studied on the basis of SWOT analysis, their products, production, value, capacity, and other vital factors.

The objectives of the report are:

To analyze and forecast the market size of Automobile AntennaIndustry in theglobal market. To study the global key players, SWOT analysis, value and global market share for leading players. To determine, explain and forecast the market by type, end use, and region. To analyze the market potential and advantage, opportunity and challenge, restraints and risks of global key regions. To find out significant trends and factors driving or restraining the market growth. To analyze the opportunities in the market for stakeholders by identifying the high growth segments. To critically analyze each submarket in terms of individual growth trend and their contribution to the market. To understand competitive developments such as agreements, expansions, new product launches, and possessions in the market. To strategically outline the key players and comprehensively analyze their growth strategies.

Get Full Report @ https://garnerinsights.com/2013-2028-Report-on-Global-Automobile-Antenna-Market-by-Player-Region-Type-Application-and-Sales-Channel

The growth of this market globally is subjected to various factors, including consumer ace Automobile Antennaof a lot of Automobile Antennaproducts, inorganic company growth models, price volatility of raw materials, product innovation along with economic prospects in both producer and consumer countries.

Conclusively, This report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Contact Us:Mr. Kevin Thomas+1 513 549 5911 (US)+44 203 318 2846 (UK)Email: [emailprotected]

Read the original:
Cell Processing Technologies Market Advance Technology And New Innovations By 2027 Illuminated By New Report - Melanian News

Spinal Cord Stem Cells Comments Off on Cell Processing Technologies Market Advance Technology And New Innovations By 2027 Illuminated By New Report – Melanian News | January 22nd, 2020

The first squeeze of my left thumb is gentle, almost reassuring. I rate it as 0 out of 100 on the pain scale.

But as a technician ramps up pressure on the custom-made thumb-squeezing device, it becomes less pleasant. I give ratings of 2, 6 then 36. A few squeezes later, Im at 79.

At 84, Im glad the test is over as I put my tender thumb to my lips.

Ive offered myself up for a pain study at the University of Michigan, in a long, low-slung building northeast of the universitys main campus in Ann Arbor. As the day wears on, Ill undergo needle pokes, leg squeezes and an MRI scan all part of a grand bid tobetter understand the root cause of an individuals pain, and point to the best solutions.

Its an understanding thats sorely needed. Lucky for me, Im just a control in this experiment, and I can cry for mercy whenever I want. Thats not the case for the multitudes of people 50 million in the US alone who have ongoing, chronic pain, for whom the medical pause buttons are far from adequate.

The thumb pressure test, in which participants rate their pain level on a scale from 0 to 100 as their thumbs are subjected to increasing pressure, is one of several ways that clinicians and researchers can evaluate a persons pain responses. Since peoples thresholds to pain in tests like this vary according to pain syndrome, such tests can help with diagnosis. (Credit: Amber Dance)

Our treatments for chronic pain are very bad, says Richard E. Harris, a neuroscientist at the University of Michigans Chronic Pain and Fatigue Research Center and a co-researcher on the study, which should ultimately help to improve diagnoses and therapies. Today, doctors mostly define pain by where it is: the abdomen, the lower back, the joints. Then they offer up treatments, usually anti-inflammatories or opioids, that too often do nothing to the cells and molecules causing a person to hurt. A recent analysis in theJournal of the American Medical Associationfound thatopioids reduced pain by an average of less than one point on a 10-point scale, across a variety of chronic conditions.

As part of the precision medicine movement and thanks to modern brain-imaging technology, scientists are starting to puzzle out the different types of pain: what causes them, how to diagnose them and how to prescribe treatments to match. Its an area that is far from settled. As recently as 2017, the International Association for the Study of Pain defineda new pain type, called nociplastic. Its characterized by the absence of any nerve or tissue damage in the parts that hurt.

Dan Clauw, director of the Michigan pain center, is passionate about helping people with this kind of long-misunderstood pain, which could underpin chronic conditions, such as fibromyalgia, that afflict millions. His blue eyes flash behind spectacles as he describes crisscrossing the globe to educate other physicians about nociplastic pain. Hes wearing a navy blazer and slacks when we meet for lunch between my testing sessions, because hes just returned from giving a presentation about marijuana and pain. He jokes that his colleagues wont recognize him out of his usual jeans.

Imaging the brain, along with doing prodding and poking tests of the type I endured, is beginning to point to signatures that explain the problem and suggest solutions. Eventually, this knowledge will help scientists to develop more targeted therapies, so doctors can treat patients better.

In broad strokes, pain falls into three categories: nociceptive, neuropathic and nociplastic. (Noci- is from the Latin for to do harm.)

Nociceptive pain results from inflammation or direct damage to tissues. When thattorture devicesqueezes my thumb, for example, pain-sensing nerves notice the pressure and spring into action. They transmit messages to my spinal cord, which sends them on to my brain, telling me Ouch!

This kind of discomfort is often short-lived; mine dissipates after Ive sucked on my thumb for a few moments. Nociceptive pain can also be chronic, though for example in osteoarthritis, where the cartilage in joints wears away and causes stretching of tendons and ligaments, or through the ongoing inflammation of rheumatoid arthritis.

Neuropathic pain, in contrast, happens when the pain-sensing nerves themselves are damaged or irritated, so that they send inappropriate Ow! signals to the brain. It typically results from some injury or disease, such as diabetes or shingles. It can also happen when a nerve is pinched, as in the case of carpal tunnel syndrome, when a nerve in the wrist gets squeezed. Its often long-lasting, unless the damage is repaired.

And nociplastic, the newly named type, results from no obvious inflammation or injury. Rather, its as if the volume knob for pain is turned up way too high, not at the pain site itself but further afield. Nociplastic pain seems to arise in parts of the central nervous system the brain or spinal cord that receive, transmit or process those Ouch! signals. These nerves misfire, creating a sensation of pain even though nothing may be wrong. The location of the problem, the central nervous system, is why Clauw prefers to call it central sensitization. The classic example is fibromyalgia, which causes pain that seems to stem from muscles, tendons and joints, despite the real problems lying in the brain or spinal cord.

Scientists understanding of pain continues to evolve and so do the various terms used to describe it. Ideally, definitions are standardized and reflect the biology underpinning the pain, but the lack of straightforward tests for parsing types of pain makes defining it a challenge. Nociceptive pain involves pain-sensing nerves called nociceptors, which also can be involved in neuropathic pain. A third pain type is believed to arise wholly in the central nervous system. But there can be overlap: Nociceptive and neuropathic pain can, over time, lead to central nervous system-generated pain.

Complicating the picture, a person might have more than one type of pain going on at the same time. In 2012, the journalPainpublished a case report of a person with burning, prickling pain on both sides of the body. Treatment with pregabalin, an epilepsy medication that can also address neuropathic pain and central sensitization,relieved pain on the right side of the body, but not the left.

All this pain classifying is more than an academic exercise: It should help guide how to treat people. For example, consider a patient with knee pain. If the issue is nociceptive, anti-inflammatories or knee surgery should help. But if the problem is central, those treatments probably wont make much difference. A better bet would be medications that can directly influence the misfiring central nervous system. Some antidepressants, for example, act on the brains chemical messengers neurotransmitters that are involved in pain, altering their signaling to quell the Ouch message.

Non-drug treatments such as acupuncture and cognitive behavioral therapy also may help because they influence how the brain perceives pain. Acupunctureboosts availability of brain receptors that respond to the bodys natural painkillers. A recent analysis inJAMA Internal Medicineof more than 6,000 people taking opioids found that treatments such as meditation, hypnosis and cognitive behavioral therapyreduced pain and diminished the drug doses needed to control it.

Though the term nociplastic is new, Clifford Woolf, a neurobiologist at Boston Childrens Hospital and Harvard Medical School,first proposed the concept in 1983. Yet the idea has been slow to catch on. In the 1990s, when Clauw began studying fibromyalgia, it was a disease so vague, so puzzling, that some physicians simply denied its existence.

Today, fibromyalgia is more likely to be accepted as a real condition. But many doctors still dont appreciate how centralized problems might underlie pain even when the symptoms look nociceptive or neuropathic, Clauw says. The distinctions between pain types are not clean: If left untreated, nociceptive pain may sensitize the nervous system, turning a temporary problem into chronic, nociplastic pain, for example. Clauw and his Michigan colleagues believe that central sensitization shows up in myriad conditions, from irritable bowel syndrome to chronic pelvic pain to dry eye disease. And in the study Ive signed up for, they want to clarify how often this happens and how doctors might detect it in patients who show up begging for pain relief.

To that end, the team has enrolled people with three different pain disorders that seem, on the surface, to be nociceptive or neuropathic. The scientists will test their pain before and after standard treatments. If the pain is in fact central, the treatments shouldnt work a disappointment for the participants, but one that might eventually lead to better understanding and treatment for them and others like them.

Two categories of subjects have what looks like nociceptive pain: those with osteoarthritis of the hip, who will receive a hip replacement, and those with inflammatory rheumatoid arthritis, who will be treated with modern medications. A third group, people with carpal tunnel syndrome, represent neuropathic pain and will get surgery to receive the pressure on the nerve.

But if Clauw and his crew are right, then some of these people will really be suffering from central sensitization, instead of or in addition to the nociceptive or neuropathic problem. Two control groups will help tease that out: People with fibromyalgia will show the researchers what pure central sensitization looks like, and those like me, with no chronic pain, will represent the non-central state.

The primary way that physicians measure pain today is to ask someone how much theyre hurting. Identification of biomarkers from, for example, brain imaging or blood tests could provide more objective measures of pain that would offer benefits in a variety of settings.

Once all the data are in, the researchers hope that pain features shared by the people with fibromyalgia and the others whose treatments dont work will reveal a potential signature for central sensitization.

The challenge is that theres no simple blood test or X-ray that will distinguish one type of pain from another. Theres no single measure that, by itself, will represent pain, says Woolf, author of a paper in theAnnual Review of Neuroscienceabout pain caused by problems in the sensory machinery. We need a composite.

To build that composite, scientists must resort to a variety of indirect measures, including responses to the pokes and prods being inflicted on me and other subjects.

This particular piece of the picture, called quantitative sensory testing or QST, measures the threshold at which a person can feel a given sensation such as pressure, heat or cold and when that sensation becomes painful. This can reveal how a persons nervous system deals with pain, and how that system might be off-kilter. Specific defects in nerves lead to specific changes in pain responses, helping scientists to distinguish one pain type from another.

Its simple, but revealing. For example, in the case of the thumb-press test, a person with fibromyalgia would probably start to feel pain at around four pounds of pressure. Clauw, who has no chronic pain of any stripe and is relatively pain-insensitive, says that he can handle up to about 18 pounds of pressure before it becomes uncomfortable. The average person would probably start to feel bothered at around eight pounds.

Or take a test where Im poked in the forearm with a needle. The device retracts into the handle like a Hollywood special-effects knife, so it doesnt pierce my skin, but it doesnt feel great I rate it a 7 out of 100. Then I get 10 pokes in quick succession. That hurts more, at 32. This is a normal response, but if I had central sensitization, I would likely have found the 10-poke series much more painful.

In addition to sorting out nociceptive or neuropathic from centralized pain, QST also seems able to reveal subtypes. In research published in 2017, three European consortia performed QST on 900 people with diverse pain conditions, all considered to be neuropathic. The testingseparated the subjects into three clusters, and the study authors predicted that each would be suited to different treatments.

Better-defined markers for different types of pain could radically improve pain management. As shown, it would allow patients to be sorted into clinical trials that would reveal the best treatments for each pain subtype. Results of those trials would help physicians treat individual patients more effectively.

The first cluster was characterized by deficits in sensation to touch, heat or pokes that would normally be painful. This suggests that central sensitization might be behind the pain in some of these people, says study coauthor Nadine Attal, a pain specialist at the Assistance Publique-Hpitaux de Paris. Opioids, antiepileptics or antidepressants (used for their effects on pain nerves, not mood) might help, because they act in the brain.

The second group was defined by extreme sensitivity to hot and cold like skin when its sunburned, which puts pain-sensing nerves on high alert. For this kind of neuropathic pain, local, numbing medications such as lidocaine, Botox or capsaicin (a therapeutic substance from hot peppers) might be the right choice.

People in the third group were particularly sensitive to pressure and pinpricks, and its members often reported pain akin to burning or electrical shock. This was a more complex group, Attal says; she thinks topical medications or antiepileptics might help. But now that researchers have the categories better defined, they can directly test medications to find what truly works best for each.

Looking at the brain in pain also can help scientists distinguish pain types, although the answers arent clear-cut. Theres no one, lone spot where pain lights up the brain, says Sean Mackey, chief of the division of pain medicine at Stanford University in California. Rather, the pain response is distributed across a circuit that encompasses several brain areas.

In the afternoon of my day as a pain-study subject, Im led to the universitys North Campus for an MRI. The technician slides me into a gray, General Electric-branded, upright donut about the size of a golf cart. The outside is festooned with frolicsome animal stickers (many subjects from other studies are children), but these do nothing to allay the discomfort of lying perfectly still with my head in a vise for an hour and a half.

As I lie there, listening to the scanners inharmonious beeps, rumbles and alien-laser-gun sounds, Im not thinking of anything in particular. Nonetheless, certain parts of my brain tend to draw blood at the same time, suggesting that theyre acting in sync. These are called networks.

Roughly half of people with rheumatoid arthritis experience pain even when using medications that control the inflammation. MRI scans of some of these patients reveal amped up connectivity between two brain regions, the default mode network and insula. This brain connectivity also has been found in people with fibromyalgia, a chronic pain condition with roots in the central nervous system. The discovery suggests that rather than inflammation alone, a dysfunctional central nervous system can also play a role in the pain of rheumatoid arthritis. (Credit: Image acquired and generated from the Chronic Pain and Fatigue Center with assistance from the FMRI laboratory at the University of Michigan)

One that Harris and colleagues are particularly interested in is called the default mode network. It turns on when Im at rest and my mind wanders to topics involving myself: what I had for breakfast, perhaps, or what Im planning for tonight once my day of pain is over.

Another network theyre watching is the salience network, which lights up when a person notices a new sensation say, the squeezing of their thumb to determine which sensations are worth responding to. It includes the insula, a pyramid-shaped bit of brain that Mackey and others have linked to pain.

Normally, the insula and the default mode network are unlikely to act at the same time. But Harris and colleagues discovered that in people with fibromyalgia,they were much more likely to flash in synchrony.

That makes sense, says Rob Edwards, a pain psychologist at Harvard Medical School and Brigham and Womens Hospital in Boston. For someone living with chronic pain, the pain can become a core part of their identity. The salience-related threat intrudes on, and even takes over, the way that you think about yourself, he says.

It may be possible to undo that intrusion, though. Edwards is currently testing cognitive behavioral therapy, or CBT, in people with fibromyalgia. In no way is he suggesting that their pain, or any pain, is imaginary, but therapy can help people deal with pain better and even reduce it. Its all about enforcing a sense of control and mastery, says Bob Kerns, a pain psychologist at Yale University in New Haven, Connecticut, who coauthored a paper in theAnnual Review of Clinical Psychologyonpsychological treatment for chronic pain.

In the study so far, CBT seems to be disentangling the salience and default mode networks in some people with fibromyalgia. Edwards predicts those people will also experience pain relief.

Being able to forecast who will benefit from a given treatment could make a huge difference not just for individual patients, but also in clinical trials for new pain-relief drugs. If scientists test a pain drug on 100 people, but only a fraction of those subjects actually have the pain mechanism the drug can treat, the medicine will look like a flop even if its a superstar for a particular subset of patients. This has almost certainly happened in past trials, Woolf says.

Mackey envisions a future in which pain patients can be tested for the underlying problem, perhaps with the same kinds of tests I underwent at the University of Michigan, plus many more assessments. For example, scientists are analyzing nerve endings in small skin samples from pain patients, and others aim to tease outthe role of genetics in chronic pain. Simple questionnaires can also help to identify pain types, all with this goal of prescribing medications tailored for a persons specific flavor of misery.

Medicine isnt quite there yet in fact, only 10 years ago Mackey would have called that scenario science fiction. Stay tuned, he says, because its no longer science fiction. . . . Were going to get there.

As required by the University of Michigan Institutional Review Board, Amber Dance was compensated $275 for her participation in the study at the Chronic Pain and Fatigue Research Center. She donated that amount tothe American Chronic Pain Association.

This article originally appeared in Knowable Magazine, an independent journalistic endeavor from Annual Reviews.

Read the original here:
There's More Than One Type of Pain. Scientists Are Learning to Treat Each of Them - Discover Magazine

Spinal Cord Stem Cells Comments Off on There’s More Than One Type of Pain. Scientists Are Learning to Treat Each of Them – Discover Magazine | January 22nd, 2020

By GREGORY ZELLER //

That light at the end of the tunnel comes from the Northwell Health Cancer Institute, which provided hope and bona fide bone marrowy health improvements to a record number of patients last year.

As 2019 ticked down, staffers of the NHCIs Don Monti Adult Stem Cell Transplant Program gathered inside North Shore University Hospitalto recognize what Ruthee Lu-Bayer, chief of the Don Monti Bone Marrow Transplantation Unit, called a monumental milestone: the units 100th stem cell transplant of the year.

While any cancer clinic worth its salt is going to embrace hope, joy can be a rare commodity but the 100th stem cell transplant of 2019 triggered a full-on celebration at the Manhasset hospital, where stem cell transplants began in 1987 and are now performed in the 10-bed, inpatient Don Monti unit.

Complete with balloons, cake and a salute to No. 100 herself cancer-battling patient Teresa OHalloran the celebration assembled the units myriad doctors, nurses and other professionals, with Bayer applauding the combined efforts of every member of our staff who made this moment happen.

I always say that getting through their diagnosis is half the battle, the board-certified medical oncologist noted. When our patients arrive for transplant, I ask them to think of their transplant date as their second birthday, a time when they can begin to live their lives again.

Century mark: Don Monti Bone Marrow Transplantation Unit chief Ruthee Lu-Bayer and No. 100, Teresa OHalloran.

The gathering was also a celebration of the patients themselves, Bayer added, including OHalloran, whos fighting back against adult acute myeloid leukemia, a type of cancer in which the bone marrow produces abnormal white blood cells.

The 62-year-old East Islip resident, known affectionately as No. 100 around the unit, received the tough diagnosis last August and was admitted to NSUH in December for a bone marrow transplant. Following several days of preparatory chemotherapy, she received her infusion as the calendar flipped to 2020 and is now making an unusually rapid recovery, according to Northwell Health.

OHalloran, who joined the celebration from the safety of her isolated recovery room, credits her faith and positive outlook Ive always looked at the glass as half full, she noted and urged potential stem cell donors to check in with Be The Match, the national, nonprofit marrow-donor program.

I wish everyone could understand how important it is to be tested as a possible match, OHalloran added. Its a simple cheek swab and you could wind up saving someones life.

Read the original:
At NSUH, a cell of the century in the Don Monti unit - Innovate Long Island

Bone Marrow Stem Cells Comments Off on At NSUH, a cell of the century in the Don Monti unit – Innovate Long Island | January 22nd, 2020

New cell treatment could help maintain healthy blood sugar levels

A new cell treatment to enhance islet transplantation could help maintain healthy blood sugar levels in Type 1 diabetes without the need for multiple transplants of insulin producing cells or regular insulin injections, research suggests.

In Type 1 diabetes the insulin-producing cells of the pancreas are destroyed. Insulin injections maintain health but blood glucose levels can be difficult to control. Currently in the UK it is estimated that approximately 400,000 people in the UK have type 1 diabetes.

The current recommendation for people with type 1 diabetes who have lost awareness of low blood glucose levels is the transplantation of islets the insulin producing part of the pancreas.

A study in mice found that transplanting a combination of islets with connective tissue cells found in umbilical cords known as stromal cells - could potentially reduce the number of pancreases required for the procedure.

Mice that received the islet-stromal cell combination were found to have better control of blood glucose and less evidence of rejection of islets after seven weeks, compared to those that received islets alone.

In humans, more than two donor pancreases, which are scarce, are often needed because islets can be rejected and are slow to form new blood supplies.

Therefore, multiple islet transplantations and anti-rejection medication are required to control blood sugar levels in people with Type 1 diabetes. Scientists at the University of Edinburgh hope their findings could be a way of overcoming these issues.

The researchers found that islets combined with stromal cells successfully returned normal blood glucose levels just three days after transplantation.

Other studies have used cells sourced from bone marrow and fat. This is the first to use stem cells from umbilical cords and has produced superior results.

The research is published in the journal Science Translational Medicine and funded by Chief Scientist Office in Scotland and Diabetes UK.

Shareen Forbes, Professor of Diabetic Medicine at the University of Edinburgh and Lead Physician for the Islet Transplant Program in Scotland, said: Should this research prove successful in humans, we could reduce the number of islets needed to control blood sugar levels using this co-transplantation approach. This would mean more people with Type 1 diabetes could be treated using islet transplantation while significantly reducing the waiting time on the transplant list.

John Campbell, Professor and Associate Director Tissues, Cells & Advanced Therapeutics at the Scottish National Blood Transfusion Service has said that further work is needed to establish the long-term safety of using this type of stromal cell in this setting before proceeding to clinical trials in humans.

Dr. Elizabeth Robertson, Director of Research at Diabetes UK, said: Islet transplants have been life changing for some people with Type 1 diabetes, treating dangerous hypo unawareness. But there currently arent enough donated pancreases to go around, and the procedure itself isnt yet as effective as it could be.

This new research from the University of Edinburgh is a promising step forward, and one we hope will lead to islet transplants becoming both more effective and more widely available in the future.

Register for your free SelectScience membership today to receive the latest editorial articles and technology news direct to your inbox>>

Read the rest here:
Cell therapy trialed in mice offers diabetes treatment hope - SelectScience

Bone Marrow Stem Cells Comments Off on Cell therapy trialed in mice offers diabetes treatment hope – SelectScience | January 22nd, 2020

Janssen has announced that the European Commission (EC) has grantedmarketing authorisationfora new Darzalex (daratumumab) combo, for newly diagnosed, transplant eligible patients with multiple myeloma (MM).

On the news, the combination, which consists of the biologic combined with bortezomib, thalidomide and dexamethasone(VTd) is now the first regimen approved in over six years for newly diagnosed patients who are eligible for a stem cell transplant. It also means that the patient population now has their first opportunity to be treated with a monoclonal antibody.

The company says that the approval was based on results from part one of the Phase III CASSIOPEIA (MMY3006) study, which showed that after consolidation, the stringent complete response (sCR) rate was 9% higher in the Darzalex-VTd arm than the VTd alone arm.

Further, at a median follow-up of 18.8 months, PFS was significantly improved in the Darzalex-VTd group, with the addition of the drug resulting in an 18-month PFS rate of 93%, compared to 85% for VTd alone.

The effectiveness of first line treatment is critical to maximise time until relapse, explained Philippe Moreau, principal investigator and Head of the Haematology Department at the University Hospital of Nantes.

He continued, The CASSIOPEIA study answered that question definitively, demonstrating that the addition of Darzalex in combination with VTd can lead to very deep remissions and also prolong PFS. Im pleased to see the European Commission have recognised this as well.

MM is an incurable blood cancer that starts in the bone marrow and is characterised by an excessive proliferation of plasma cells. In Europe, more than 48,200 people were diagnosed with MM in 2018, with more than 30,800 deaths related to the disease.

Originally posted here:
Darzalex EU nod marks first newly diagnosed MM treatment in six years - PharmaTimes

Bone Marrow Stem Cells Comments Off on Darzalex EU nod marks first newly diagnosed MM treatment in six years – PharmaTimes | January 22nd, 2020

When enlarged under a high-resolution microscope, microglia resemble elegant tree branches with many slender limbs. As they pass by neurons, microglia extend and retract their tiny arm-like protrusions, tapping on each neuron as if to inquire, Are we good here? All okay? Or not okay?as a doctor might palpate a patients abdomen, or check reflexes by tapping on knees and elbows.

Back in 2004, Barres and Stevens were examining how synapses originally come to be pruned to form a healthy brain during early, normal development. Theyd recently discovered that immune molecules known as complement were sending out eat me signals from some brain synapses, and these synapsestagged with a kind of kiss of death signagewere destroyed. Think of the way you click and tag emails that you want deleted from your inbox. Your email servers software recognizes those tags, and when you click on the Trash icon, bing, theyre gone. Thats similar to what Stevens and Barres were seeing happen to brain synapses that were tagged by complement. They disappeared.

What they described happening in the brain, which they reported in the journal Cell in 2007, echoed a similar process that was well-understood to happen in the body. When a cell dies in a bodily organ, or if the bodys immune system senses a threatening pathogen, complement molecules tag those unwanted cells and invaders for removal. Then, a type of white blood cell known as macrophagesGreek for big eatersrecognizes the tag, engulfs the cell or pathogen, and destroys it. In the body, macrophages play a role in inflammation as well as in autoimmune diseases like rheumatoid arthritis and Guillain Barre. When activated, they can mistakenly go too far in their effort to engulf and destroy pathogens and spew forth a slew of inflammatory chemicals that begin to do harm to the bodys own tissue.

Stevens and Barres werent sure what was eating away at these tagged synapses, causing them to disappear in the brain, but Stevens had a hunch that it might have something to do with microglia.

We could see that when microglia sensed even the smallest damage or change to a neuron, they headed, spider-like, in that neurons direction, then they drew in their limbs and morphed into small, amoeba-like blobs, Stevens says. Soon after, those same synapses disappeared. Poof.

Could microglia be the culprit at the center of it all, the macrophage corollary in the brain, responding to eat me signals and pruning the brains circuitry during development? And what if this process was not only taking place in utero? Stevens wondered, when she first saw microglia behaving this way. What if it was also being mistakenly turned back on again later in life, during the teen years, or in adulthoodonly now its a bad thing and microglia are sometimes mistakenly engulfing and destroying healthy brain synapses too?

You can imagine how you could have too many synapses, or not enough synapse connectivity, Stevens says, her hands spreading wide with excitement. And you can imagine, given how our brain works, if that connectivity is even slightly off, that could potentially underlie a range of neuropsychiatric and cognitive disorders.

When she landed at Harvard, Stevens and her postdoc, Dori Schafer, tried to get a closer look at what microglia were up to in the brain. Schafer injected dye into the eyes of mice, which she then traced down from the neurons in the eye nerves and into the brain. This made the brains synapses glow bright fluorescent red. Microglia were stained fluorescent green. If they saw structuresthe synapsesglowing like red, fluorescent lit-up dots inside the bellies of the green microglia, they would know that microglia were eating synapses.

Six months into their efforts, Schafer came running into Stevenss office with photo images flapping in her hand. Theyre in there! she told Stevens. The synapses are inside the microglia! We can see it! It was such a high-five moment, Stevens recalls. Microglia were like tiny little Pac-Men in the brainand brain synapses were in the belly of the Pac-Men! We felt we were on to something really wonderful, really novel. This was deeply important in terms of looking ahead to microglias role in disease.

See more here:
The Tiny Brain Cells That Connect Our Mental and Physical Health - WIRED

Bone Marrow Stem Cells Comments Off on The Tiny Brain Cells That Connect Our Mental and Physical Health – WIRED | January 22nd, 2020

NEW YORK and LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, will present at the 10th Annual California ALS Research Summit, January 24-25 at Cedars-Sinai Medical Center, Los Angeles, California.

Dr. Kern will provide an update on BrainStorms Phase 3 ALS Clinical Trial on Friday, January 24, 10:30 -11:10 AM PT, during the session: CIRM funded Stem Cell Clinical Trials in California Updates.

Dr. Kern stated, This prestigious Summit works to increase, expedite and promote the amount and level of amyotrophic lateral sclerosis (ALS) research done in California that has been reinforced and amplified by the international ALS scientific and medical community. I am pleased to have the opportunity to share all that BrainStorm has accomplished in our fully enrolled Phase 3 clinical trial of NurOwn(NCT03280056).

Chaim Lebovits, President and CEO of BrainStorm, stated, California continues to be a global leader in stem cell research and scientific funding. Due to Californias commitment to stem cell scientific investigation, BrainStorm is at an inflection point as we bring our investigational therapy, NurOwn, toward the submission of a biological license application. In July 2017, BrainStorm was awarded a grant of $15.9 million from the California Institute for Regenerative Medicine (CIRM) and three of Californias most prestigious medical centers: University of California, Irvine, Cedars-Sinai Medical Center, and California Pacific Medical Center have contributed immensely to advancement of NurOwn. Everyone at BrainStorm is proud Dr. Kern will have the opportunity to present to the ALS community of California all that has been accomplished due to their ongoing support and encouragement.

About The California ALS Research Summit:

The California ALS Research Summit is the tenth annual gathering of researchers, investigators, clinicians, biotech companies, government representatives, partner organizations, and advocates in ALS and related fields in the State of California.

The purpose of the Summit is to help increase, expedite and promote the amount and level of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's Disease) and related research done in California; and to foster networking, collaboration and cooperation among investigators, their peers and their colleagues to identify, develop and deliver new and effective treatments, ideas and, ultimately, cures for ALS.

The result of our efforts is an ongoing roadmap for ALS research in California, which will provide the basis for partnering within the state and other supporters to further studies to find new treatments and ultimately a cure for the disease.

About NurOwn

NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. For more information, visit BrainStorm's website at http://www.brainstorm-cell.com.

Story continues

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Or:Katie GallagherLaVoieHealthSciencesPhone: + 1 617-374-8800 x109kgallagher@lavoiehealthscience.com

Read this article:
BrainStorm Cell Therapeutics COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit - Yahoo Finance

Bone Marrow Stem Cells Comments Off on BrainStorm Cell Therapeutics COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit – Yahoo Finance | January 22nd, 2020

Debuts at the NY20 Foundation for Podiatric Medicine Meeting

HACKENSACK, N.J.,January 21, 2020 RoyalBiologics, an ortho-biologics company specializing inthe research and advancement of novel ortho-biologics solutions, todayannounced the launch of Cryo-Cord, the first DMSO-free viable umbilical cord graft.The company will be showcasing Cryo-Cord along with its new portfolio ofAutologous Live Cellular (ALC) technologies at the NY20 Foundation forPodiatric Medicine meeting, held January 24-26 in New York, NY for more than1500 clinical attendees.

The companywill feature its full suite of surgical biologic offerings at exhibit booth #322,and on the podium for Innovation Theater presentations at 10:30am on Friday1/24/20 and 12pm on Saturday 1/25/20. Thesescientific presentations will feature several products within the RoyalBiologics portfolio. At its booth, RoyalBiologics will showcase its comprehensive ALC portfolio designed to personalizelive regenerative healing for a wide variety of wound types across theorthopedics continuum.

The launch of Cryo-Cordenablesproviders with the first DMSO-free viableumbilical cord tissue. Cryo-Cord hasbeen obtained with consent from healthy mothers during cesarean sectiondelivery and is intended for use as a soft tissue barrier or wound dressing. Cryo-Cord is processed using aseptic techniques and frozenwith a proprietary cryoprotectant.

Cryo-cord offers a new enhancement to traditional wound caretherapies and we are excited to pave the way with the first DMSO-freecryoprotectant graft on the market, said Salvatore Leo, Chief ExecutiveOfficer of Royal Biologics.

Other featuredproducts at NY20 will include Maxx-Cell, which was launched as the worlds mostadvanced bone marrow aspiration device. Maxx-Celloffers a new technique to a gold standard approach of aspirating a patientsautologous bone marrow cells. Maxx-Cell however does not requirecentrifugation to deliver a final end product. The Maxx-Cell system maximizesstem and progenitor cell yields by giving the surgeon the ability toefficiently harvest bone marrow from multiple levels within the medullaryspace, while restricting dilution of peripheral blood. As a result, Maxx-Celldelivers a high, most pure enriched form of bone marrow aspirate without theneed for centrifugation.

This month, the company has alsoannounced the launch of MAGNUS, which is a DMSO-free viable cellular boneallograft and demos will be available during the conference. MAGNUS presents aunique solution to traditional viable cellular allograft technology as itutilizes a DMSO-free cryoprotectant. This novel approach to the viable cellularallograft market differentiates MAGNUS from other technologies currently available.

Leo added, We are excited to participatein NY20 and share how our Autologous Live Cellular based therapies give thesurgeons an efficient and effective way to enhance surgical outcomes by providingalternatives to conventional therapies for bone and soft tissue relatedinjuries. We also believe that in a cost-conscious industry, we can provide novelviable cellular products that provide value at the point of care.

Towatch the latest ALC product videos and learn more about the range ofregenerative medical products offered by Royal Biologics, along with a scheduleof 2020 conferences, visit http://www.RoyalBiologics.com.

About Royal Biologics

Royal Biologics is an orthobiologicscompany specializing in the research and advancement of Regenerative CellularTherapy. Its primary focus is on usingautologous bioactive cells to help promote healing in a wide range of clinicalsettings, with its portfolio of FDA-approved medical devices. For more information on its line of products,visit http://www.royalbiologics.com.

For more mediainformation, contact:

Lisa Hendrickson,LCH Communications

lisa@lchcommunications.com

516-767-8390

Read more here:
Royal Biologics Announces The Launch of CRYO-CORD The First NON-DMSO Viable Umbilical Cord Graft - OrthoSpineNews

Bone Marrow Stem Cells Comments Off on Royal Biologics Announces The Launch of CRYO-CORD The First NON-DMSO Viable Umbilical Cord Graft – OrthoSpineNews | January 22nd, 2020

First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab in combination with carboplatin

Second patient with stage 4 HER2+ metastatic breast cancer (MBC) shows 50 percent shrinkage in the primary tumor and no new signs of metastasis in the brain after treatment with leronlimab as a monotherapy

VANCOUVER, Washington, Jan. 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today additional promising results from its clinical trials evaluating leronlimab for the treatment of metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC).

New data from the first patient enrolled in the Company's metastatic triple-negative breast (mTNBC) Phase 1b/2 trial continues to show no detectable levels of circulating tumor cells (CTC) or putative metastatic cells in the peripheral blood following 15 weeks of treatment with leronlimab in combination with carboplatin.

The second patient, enrolled through an emergency investigational new drug (IND) with stage 4 HER2+ MBC that has metastasized to the liver, lung and brain, showed a 50 percent shrinkage of the primary tumor and no new metastasis in the brain after treatment with leronlimab as a monotherapy. The patient was previously treated with pertuzumab and trastuzumab for over a year and a half. This patient has been taking leronlimab since November 25, 2019 with one 700 mg dose each week.

"Recent testing of the first patient demonstrated continued absence of CTCs in all blood tubes with only one cancer-associated macrophage like cells (CAMLs) in one of two tubes. In the second patient, the follow up brain scan conducted on January 17, 2020, showed that the largest brain lesion had a greater than 4-fold reduction in size," said Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn. "Other smaller lesions on the second patient's brain have not changed in size and cerebral edema remains at decreased levels since the last imaging studies. Taken together, these results suggest continued response of both primary and metastatic tumors to treatment with leronlimab for both the first and second patient."

Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, added: "We are thrilled to see these additional data that further support leronlimab as a potential treatment option for patients with mTNBC and MBC. As a Company, we look forward to continuing our work in the oncology space and developing a potentially safe and effective treatment option for patients suffering from this deadly disease."

About Triple-Negative Breast CancerTriple-negative breast cancer (TNBC) is a type of breast cancer characterized by the absence of the three most common types of receptors in the cancer tumor known to fuel most breast cancer growthestrogen receptors (ER), progesterone receptors (PR) and the hormone epidermal growth factor receptor 2 (HER-2) gene.1TNBC cancer occurs in about 10 to 20 percent of diagnosed breast cancers and can be more aggressive and more likely to spread and recur.2,3Since the triple negative tumor cells lack these receptors, common treatments for breast cancer such as hormone therapy and drugs that target estrogen, progesterone, and HER-2 are ineffective.4Currently, there are no targeted therapies approved to treat triple negative breast cancer.5

About Leronlimab (PRO 140)The U.S. Food and Drug Administration (FDA) have granted a "Fast Track" designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is therefore conducting aPhase 2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additionalclinical studies when appropriate.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted "orphan drug" designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab (PRO 140) as a once-weekly monotherapy for HIV-infected patients and, plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab (PRO 140) can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Company's cash position, (ii)the Company's ability to raise additional capital to fund its operations, (iii) the Company's ability to meet its debt obligations, if any, (iv)the Company's ability to enter into partnership or licensing arrangements with third parties, (v)the Company's ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Company's ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Company's clinical trials, (viii)the results of the Company's clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company's products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Company's control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTSMedia:Grace FotiadesLifeSci Communicationsgfotiades@lifescicomms.com (646) 876-5026

Investors: Nader Pourhassan, Ph.D.President & CEOnpourhassan@cytodyn.com

Read the original post:
Impressive Results Continue from CytoDyn's Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC - Benzinga

Bone Marrow Stem Cells Comments Off on Impressive Results Continue from CytoDyn’s Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC – Benzinga | January 22nd, 2020

Transparency Market Research (TMR)has published a new report on the globalcell separation technology marketfor the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~US$ 5 Bnin 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Overview

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such asstem cellresearch and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

Planning To Lay Down Future Strategy? Request Brochure Of Cell Separation Technology Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach73%, and in developing counties,70%deaths are estimated to be caused by chronic diseases. Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

To Obtain All-Inclusive Information On Forecast Analysis Of Cell Separation Technology Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1925

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from962 millionin 2017 to2.1 billionin 2050 and3.1 billionby 2100.

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development ofmicrofluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

Stem Cell Research to Account for a Prominent Share

Stem cell is a prominent cell therapy utilized in the development of regenerative medicine, which is employed in the replacement of tissues or organs, rather than treating them. Thus, stem cell accounted for a prominent share of the global market. The geriatric population is likely to increase at a rapid pace as compared to the adult population, by 2030, which is likely to attract the use of stem cell therapy for treatment. Stem cells require considerably higher number of clinical trials, which is likely to drive the demand for cell separation technology, globally. Rising stem cell research is likely to attract government and private funding, which, in turn, is estimated to offer significant opportunity for stem cell therapies.

Biotechnology & Pharmaceuticals Companies to Dominate the Market

The number of biotechnology companies operating across the globe is rising, especially in developing countries. Pharmaceutical companies are likely to use cells separation techniques to develop drugs and continue contributing through innovation. Growing research in stem cell has prompted companies to own large separate units to boost the same. Thus, advancements in developing drugs and treatments, such as CAR-T through cell separation technologies, are likely to drive the segment.

As per research, 449 public biotech companies operate in the U.S., which is expected to boost the biotechnology & pharmaceutical companies segment. In developing countries such as China, China Food and Drug Administration(CFDA) reforms pave the way for innovation to further boost biotechnology & pharmaceutical companies in the country.

Global Cell Separation Technology Market: Prominent Regions

North America to Dominate Global Market, While Asia Pacific to Offer Significant Opportunity

In terms of region, the global cell separation technology market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market in 2018, followed by Europe. North America accounted for a major share of the global cell separation technology market in 2018, owing to the development of cell separation advanced technologies, well-defined regulatory framework, and initiatives by governments in the region to further encourage the research industry. The U.S. is a major investor in stem cell research, which accelerates the development of regenerative medicines for the treatment of various long-term illnesses.

The cell separation technology market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in healthcare expenditure and large patient population, especially in countries such as India and China. Rising medical tourism in the region and technological advancements are likely to drive the cell separation technology market in the region.

Launching Innovative Products, and Acquisitions & Collaborations by Key Players Driving Global Cell Separation Technology Market

The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.

These players have adopted various strategies such as expanding their product portfolios by launching new cell separation kits and devices, and participation in acquisitions, establishing strong distribution networks. Companies are expanding their geographic presence in order sustain in the global cell separation technology market. For instance, in May 2019, Akadeum Life Sciences launched seven new microbubble-based products at a conference. In July 2017, BD received the U.S. FDAs clearance for its BD FACS Lyric flow cytometer system, which is used in the diagnosis of immunological disorders.

Visit link:
Cell Separation Technology Market to Receive Overwhelming Hike in Revenues by 2027 Dagoretti News - Dagoretti News

Cardiac Stem Cells Comments Off on Cell Separation Technology Market to Receive Overwhelming Hike in Revenues by 2027 Dagoretti News – Dagoretti News | January 20th, 2020

Global Exosome Therapeutic Marketreport identifies and analyses the emerging trends along with major drivers, challenges and opportunities in industry with analysis on Market trends, share, growth,demand, top vendors, Geographical Regions, types, applications. Exosome Therapeutic industry report gives a comprehensive account of the Global Exosome Therapeutic market. Details such as the size, key players, segmentation, SWOT analysis, most influential trends, and business environment of the market are mentioned in this report.

Exosome Therapeutic Marketis expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Download Exclusive PDF Sample Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=glo

Synopsis of Global Exosome Therapeutic Market:-Exosomes is used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Some Of The Major Competitors Currently Working In Global Exosome Therapeutic Market Are:Bayer AG, Iso-Tex Diagnostics, Inc., Bracco Diagnostic Inc., Novalek Pharmaceuticals Pvt. Ltd., iMAX, Taejoon Pharm, Unijules Medicals Ltd, General Electric, Guerbet LLC, J.B.Chemicals & Pharmaceuticals Ltd among others players domestic and global. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

For More Information or Query or Customization Before Buying, Visit @https://www.databridgemarketresearch.com/inquire-before-buying/?dbm

North America Dominates The Exosome Therapeutic Market as the U.S. Is leaderin exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Browse in-depth TOC on Exosome Therapeutic Market

50 Tables

250 No of Figures

150 Pages

This Exosome Therapeutic Market report contains all aspects that are directly or indirectly related to the multiple areas of the global market. Our experts have carefully collated the global Exosome Therapeutic Market data and estimated the change in the forecast period. This information in the report helps customers make accurate decisions about market activity Exosome Therapeutic Market based on forecasting trends. This report also discusses current or future policy research or regulations that must be initiated by management and market strategies.

Buy This Report (Single User Access)@https://www.databridgemarketresearch.com/checkout/buy/singleuser/gl

Global Exosome Therapeutic Market Scope and Market Size

Global Exosome Therapeutic Market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.To be continued..Detailed Segmentation ofExosome Therapeutic Market

The Countries Covered In The Exosome Therapeutic Market Report Are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, South Africa, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil and Rest of South America as part of South America.

Along with the elaborated information about the key contenders, the globalExosome Therapeutic Marketreport efficiently provides information by segmenting the market on the basis of the type services and products offerings, form of the product, applications of the final products, technology on which the product is based, and others. The report is also bifurcated the market on the basis of regions to analyze the growth pattern of the market in different geographical areas.

The Exosome Therapeutic Market report includes the leading advancements and technological up-gradation that engages the user to inhabit with fine business selections, define their future-based priority growth plans, and to implement the necessary actions. The global Exosome Therapeutic Market report also offers a detailed summary of key players and their manufacturing procedure with statistical data and profound analysis of the products, contribution, and revenue.

Global Exosome Therapeutic Market Report includes Detailed TOC points:

1 Introduction

2Market Segmentation

3 Market Overview

3.3 Opportunities

4 Executive Summaries

5 Premium Insights

6 Regulatory Procedure

7 Global Exosome Therapeutic Market, By Type

8 Global Exosome Therapeutic Market, by disease type

9 Global Exosome Therapeutic Market, By Deployment

10 Global Exosome Therapeutic Market, By End User

11 Global Exosome Therapeutic Market, By Distribution Channel

12 Global Exosome Therapeutic Market, By Geography

13 Global Exosome Therapeutic Market, Company Landscape

14 Company Profile

Continued!!!

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See the rest here:
Exosome Therapeutic Market 2020 Modest Situation among the Top Manufacturers, With Sales, Revenue and Market Share 2026 Dagoretti News - Dagoretti...

Cardiac Stem Cells Comments Off on Exosome Therapeutic Market 2020 Modest Situation among the Top Manufacturers, With Sales, Revenue and Market Share 2026 Dagoretti News – Dagoretti… | January 20th, 2020

The first six months of his young life have been a roller-coaster but Mighty Hudson Cowie is back home in Alberta after an experimental gene therapy procedure in Tennessee was successful.

Its been so long since weve got to see our family, our friends, Hudsons dad Ian said. Even just to be able to show him off to everybody. Weve spent the last six months seeing how amazing of a little guy he is.

Now we finally get to share that with everybody.

Hudson was diagnosed with Severe Combined Immunodeficiency (SCID) within days of his birth on June 23. The condition, known to many as Bubble Boy Disease, prevents his body from fighting illnesses. Essentially, he didnt have an immune system.

READ MORE:Hundreds attend donor drive for Mighty Hudson, Alberta baby with rare immune disease

In August, Hudson was accepted into a gene therapy program at St. Jude Childrens Research Hospital in Memphis. A medical team removed some of his bone marrow cells and replaced the faulty gene with a corrected one. The cells were placed back into his body through an IV.

Story continues below advertisement

They took his own bone marrow out in his bone marrow, hes got hematopoietic stem cells. They were able to take those cells and modify them to create a product, a repaired version of those cells, and then give them back to him, Ian told Global News on Monday.

Medicine is amazing. We took a chance on science and were so glad that we did. Its amazing what theyre able to do.

Ian and his wife Hayley were weighing two options for their little boy: using donor cells or a revamped version of Hudsons own cells. They decided on the second, which meant a trial at St. Judes.

We weighed the pros and cons of both options and for us, [and] personally, we decided that gene therapy seemed like the safer way to go, Ian said.

It didnt rely on a donor, it was the new up-and-coming medicine, the existing results for gene therapy were already incredibly promising and then, as an added bonus, it had substantially less chemotherapy requirements.

Story continues below advertisement

WATCH: (Sept. 9, 2019) A Morinville baby with a rare disorder received a life-changing procedure in the U.S. Hudson Cowies parents give Su-Ling Goh an update on therapy for his immune system.

It honestly sounded too good to be true, Hayley added.

With bone marrow transplant, we heard of graft versus host disease, where its somebody elses cells and they can reject them. With gene therapy, having his own cells, he wasnt going to reject them because his body already knows them.

A few months after the transplant, they started to see results: Hudsons first T-cells, a type of white blood cell thats a key component of the immune system.

From three months, it exploded. At four months, it was even more T-cells. The growth was exponential, Ian said.

Story continues below advertisement

I think thats the thing every doctor hopes to get to say to their patients one day: Hes cured. And the day that we left Memphis, she said that. She said: Hes cured.

We squealed like little schoolgirls. It was very exciting.

Hudsons immune system right now can be compared to that of a newborn baby.

As hes introduced to small bugs, itll just keep growing and growing and be normal, Hayley explained.

There are still unknowns, but the family is very hopeful.

He was Patient 12 on the trial and from what we were informed, everyone on the trial has done tremendously well, Ian said.

I just think its amazing, Hayley added. Its amazing that we were the first ones who got on newborn screening and that this trial was even available for us. It just seems that everything completely lined up.

Story continues below advertisement

I feel like everything has just fallen into place to get him cured.

The treatment is just amazing. Our doctors are brilliant, its just all incredible and hes doing great.

Hudson was one of the first babies to be screened for SCID through a new program. Since SCID was added in May 2019, the Alberta Health Services Newborn Metabolic Screening Program has screened over 34,000 newborns and has diagnosed four cases of SCID.

While very much welcome, being home is still a big change for the Cowies.

Im still processing, even now, Hayley said. Its nice to go see people but we were in isolation for so long that it doesnt just flip all of a sudden. I know were still really protective and we can hear a cough from miles away.

Story continues below advertisement

It was surreal to leave but I feel like Im still dreaming a little bit.

They havent attempted any big outings yet especially given its flu season but they have been able to go to some family dinners.

Its an adjustment for sure, but a good adjustment, Hayley said. He loves people Hes always just smiling and playful hes just happy.

The Cowies will be back in Tennessee for one day for a checkup this weekend. Hudson will have another checkup with the St. Judes team next month. Hell have followups at least once a year until hes 10 years old.

2020 Global News, a division of Corus Entertainment Inc.

See the original post:
Alberta baby Mighty Hudson home after gene therapy: hes cured - Global News

Bone Marrow Stem Cells Comments Off on Alberta baby Mighty Hudson home after gene therapy: hes cured – Global News | January 20th, 2020

Warsaw (AFP)

Poland has emerged as Europe's leader in stem cell storage, a billion-dollar global industry that is a key part of a therapy that can treat leukaemias but raises excessive hopes.

Submerged in liquid nitrogen vapour at a temperature of minus 175 degrees Celsius, hundreds of thousands of stem cells from all over Europe bide their time in large steel barrels on the outskirts of Warsaw.

Present in blood drawn from the umbilical cord of a newborn baby, stem cells can help cure serious blood-related illnesses like leukaemias and lymphomas, as well as genetic conditions and immune system deficits.

Polish umbilical cord blood bank PBKM/FamiCord became the industry's leader in Europe after Swiss firm Cryo-Save went bankrupt early last year.

It is also the fifth largest in the world, according to its management, after two companies in the United States, a Chinese firm and one based in Singapore.

Since the first cord blood transplant was performed in France in 1988, the sector has significantly progressed, fuelling hopes.

- Health insurance -

Mum-of-two Teresa Przeborowska has firsthand experience.

At five years old, her son Michal was diagnosed with lymphoblastic leukaemia and needed a bone marrow transplant, the entrepreneur from northern Poland said.

The most compatible donor was his younger sister, Magdalena.

When she was born, her parents had a bag of her cord blood stored at PBKM.

More than three years later, doctors injected his sister's stem cells into Michal's bloodstream.

It was not quite enough for Michal's needs but nicely supplemented harvested bone marrow.

As a result, Michal, who is nine, "is now flourishing, both intellectually and physically," his mum told AFP.

A cord blood transplant has become an alternative to a bone marrow transplant when there is no donor available, with a lower risk of complications.

Stem cells taken from umbilical cord blood are like those taken from bone marrow, capable of producing all blood cells: red cells, platelets and immune system cells.

When used, stem cells are first concentrated, then injected into the patient. Once transfused, they produce new cells of every kind.

At the PBKM laboratory, "each container holds up to 10,000 blood bags... Safe and secure, they wait to be used in the future," its head, Krzysztof Machaj, said.

The bank holds around 440,000 samples, not including those from Cryo-Save, he said.

If the need arises, the "blood will be ready to use without the whole process of looking for a compatible donor and running blood tests," the biologist told AFP.

For families who have paid an initial nearly 600 euros ($675) and then an annual 120 euros to have the blood taken from their newborns' umbilical cords preserved for around 20 years, it is a kind of health insurance promising faster and more effective treatment if illness strikes.

But researchers also warn against unrealistic expectations.

- Beauty products -

Haematologist Wieslaw Jedrzejczak, a bone marrow pioneer in Poland, describes promoters of the treatment as "sellers of hope", who "make promises that are either impossible to realise in the near future or downright impossible to realise at all for biological reasons."

He compares them to makers of beauty products who "swear their cream will rejuvenate the client by 20 years."

Various research is being done on the possibility of using the stem cells to treat other diseases, notably nervous disorders. But the EuroStemCell scientist network warns that the research is not yet conclusive.

"There is a list of almost 80 diseases for which stem cells could prove beneficial," US haematologist Roger Mrowiec, who heads the clinical laboratory of the cord blood programme Vitalant in New Jersey, told AFP.

"But given the present state of medicine, they are effective only for around a dozen of them, like leukaemia or cerebral palsy," he said.

"It's not true, as it's written sometimes, that we can already use them to fight Parkinson's disease or Alzheimer's disease or diabetes."

EuroStemCell also cautions against private blood banks that "advertise services to parents suggesting they should pay to freeze their child's cord blood... in case it's needed later in life."

"Studies show it is highly unlikely that the cord blood will ever be used for their child," the network said.

It also pointed out that there could be a risk of the child's cells not being useable anyway without reintroducing the same illness.

Some countries, such as Belgium and France, are cautious and ban the storage of cord blood for private purposes. Most EU countries however permit it while imposing strict controls.

- Rapid growth -

In the early 2000s, Swiss company Cryo-Save enjoyed rapid growth.

Greeks, Hungarians, Italians, Spaniards and Swiss stored blood from their newborns with the company for 20 years on payment of 2,500 euros upfront.

When the firm was forced to close in early 2019, clients were left wondering where their stem cells would end up.

Under a kind of back-up agreement, the samples of some 250,000 European families were transferred for storage at PBKM.

The Polish firm, founded in 2002 with two million zlotys (around 450,000 euros, $525,000), has also grown quickly.

Present under the FamiCord brand in several countries, PBKM has some 35 percent of the European market, excluding Cryo-Save assets.

Over the last 15 months, outside investors have contributed 63 million euros to the firm, PBKM's chief executive Jakub Baran told AFP.

But the company has not escaped controversy: the Polityka weekly recently published a critical investigative report on several private clinics that offer what was described as expensive treatment involving stem cells held by PBKM.

2020 AFP

Read more:
Europe's guardian of stem cells and hopes, real and unrealistic - FRANCE 24

Bone Marrow Stem Cells Comments Off on Europe’s guardian of stem cells and hopes, real and unrealistic – FRANCE 24 | January 20th, 2020

Research team leader Marina Gomzikova, employee of the Gene and Cell Technologies Lab, started working on extracellular microvesicles (ECMVs) in 2013, when she was enrolled in her PhD course. Since then, very promising properties were found in ECMVs derived from human mesenchymal stem cells (MSCs).

ECMVs are microstructures surrounded by a cytoplasm membrane; they have proven to be a prospective therapeutic tool due to their biocompatibility, miniature size, safety, and regenerative properties. Microvesicles can be applied to circumvent the existing limitations in cell therapy without losing in effectiveness. At Kazan Federal University, cytochalasin B-induced membrane vesicles (CIMVs) are currently studied. They are derived from mesenchymal stem cells, which are very similar to natural ECMVs.

In this paper, the authors produced, studied and characterized the biological activity of MSC-derived CIMVs. A number of biologically active molecules were found in CIMVs, such as growth factors, cytokines, and chemokines; their immunophenotype was also described. Most importantly, CIMVs were found to stimulate angiogenesis, the growth of blood vessels, in the same way as stem cells.

Therefore, the team believes that human CIMVs-MSCs can be used for cell free therapy of degenerative diseases. CIMVs-MSCs are able to induce therapeutic angiogenesis, which is necessary for the treatment of ischemic tissue damage (for example, ischemic heart disease, hind limb ischemia, diabetic angiopathies, and trophic ulcers) and stimulate regeneration processes in cases of skin damage (wounds and burns), neurodegeneration (multiple sclerosis and Alzheimer's disease), or traumatic injuries (damage of peripheral nerves and spinal cord injury).

Gomzikova's group continues to research the therapeutic potential artificial microvesicles for autoimmune diseases. Vector properties, i. e. the capacity for delivery, of vesicles for tumor therapy is also of interest.

CIMVs can become a new therapeutic tool in regenerative medicine and a new class of effective and safe medications.

Continue reading here:
Studies of membrane vesicles pave the way to innovative treatments of degenerative diseases - Science Codex

Spinal Cord Stem Cells Comments Off on Studies of membrane vesicles pave the way to innovative treatments of degenerative diseases – Science Codex | January 20th, 2020

In 2019, the market size of Stem Cell Therapy Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2019 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Stem Cell Therapy .

This report studies the global market size of Stem Cell Therapy , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

This study presents the Stem Cell Therapy Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Stem Cell Therapy history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global Stem Cell Therapy market, the following companies are covered:

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Stem Cell Therapy product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stem Cell Therapy , with price, sales, revenue and global market share of Stem Cell Therapy in 2017 and 2019.

Chapter 3, the Stem Cell Therapy competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stem Cell Therapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.

Chapter 12, Stem Cell Therapy market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.

Chapter 13, 14 and 15, to describe Stem Cell Therapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.

More:
Product Innovations and Technological Advancements to Boost the Growth of the Stem Cell Therapy Market in the Upcoming Years 2017 2025 Dagoretti...

Skin Stem Cells Comments Off on Product Innovations and Technological Advancements to Boost the Growth of the Stem Cell Therapy Market in the Upcoming Years 2017 2025 Dagoretti… | January 20th, 2020

The birds and the bees as we know them are changing. A new process called in vitro gametogenesis (IVG) is currently being developed, and if successful, it will completely transform the way humans think about reproduction.

In 20 to 40 years, people will still have sex. But when they want to make babies, theyll go to a lab, predicts Stanford University Professor Henry T. Greely. Its also the premise of his book The End of Sex and the Future of Human Reproduction.

The process of IVG creates sperm and egg cells in a lab from just about any adult cell. IVG uses skin or blood cells to reverse engineer a special type of cells calledinduced pluripotent stem cells(iPSCs).

IVG could eliminate the need for egg and sperm donors. With IVG, post-menopausal women could generate viable eggs. Same-sex couples could make a biological family. Virtually anyone with skin would have the ability to produce eggs or sperm.

Although 40 years might seem a lifetime away, theres a lot to figure out before we can safely, ethically, and responsibly add in vitro gametogenesis to our list of fertility treatment options.

Read full, original post: IVG: Making Babies From Skin Cells

Originally posted here:
Video: In 40 years, babies could be made in the lab from skin cells - Genetic Literacy Project

Skin Stem Cells Comments Off on Video: In 40 years, babies could be made in the lab from skin cells – Genetic Literacy Project | January 20th, 2020